SEATTLE (September 19, 2012) – Etubics Corporation, a clinical stage bio-pharmaceutical company with a proprietary platform vaccine technology that delivers a long lasting “active” immune response against diseases, and Sanford Research in South Dakota announced that Nature’s Cancer Gene Therapy has published a peer reviewed publication entitled, “A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors.”
Human papilloma viruses (HPVs) are the causing factor of over 90% of cervical cancers and 25% of head and neck cancers. Currently, no HPV therapeutic vaccine is effective at treating established tumors, despite their success with preventing HPV infection.
Boosting the immune response with recombinant adenoviruses expressing HPV E6/E7 improves
long-term cure of HPV by as much as 30% over standard cisplatin/radiation alone. However, pre -existing adenoviral immunity severely limits the usefulness of adenovirus-based therapeutic vaccines. To negate this problem, the Etubics Platform (Ad5 [E1-, E2b-]), which induces and effective immune stimulation despite Ad5 immunity, was used in this study.
The Etubics Platform targeting E6 and E7 in HPV was shown to improve long-term survival in
pre-clinical models and when used with chemotherapy or radiation was shown to statistically enhance the clearance of established HPV+ cancer in vivo.
Dr. Frank R. Jones, founder, Chairman and Chief Executive Officer of Etubics stated, “At Etubics, we strive to utilize our Etubics Platform to create immunotherapies that target difficult-to-treat cancers. We are excited to be a part of this groundbreaking research on an HPV immunotherapy at Sanford Cancer Research Center and help to come one step closer to a meaningful therapy for HPV induced cancers.”
Dr. John Lee, surgeon and scientist at Sanford Research and principle investigator of the study,
stated, “This article provides a pre-clinical rationale to initiate testing of a therapeutic vaccine in humans. The approaches enhance HPV specific immune clearance in conjunction with standard of care chemoradiation. This approach should not increase treatment morbidity while adding an improved survival advantage for patients.”
To view the publication online, visit:
Etubics and scientists like Dr. Lee are developing the next generation in vaccines and
immunotherapies, utilizing a patented advanced generation adenovirus delivery platform and a validated manufacturing human cell line, collectively the Etubics Platform to fight many cancers. Etubics has completed a Phase I/IIa clinical trial with an immunotherapeutic product candidate to treat advanced colorectal cancer. Etubics Phase I/IIa colorectal cancer trial has been funded primarily through grants from the National Cancer Institute (NCI). The NCI also awarded earlier grants to Etubics for its colorectal and breast cancer pre-clinical studies needed to advance to l clinical work.
Etubics Corporation, based in Seattle, Wash., is a next generation clinical stage bio-pharmaceutical company, which has developed a proprietary platform technology consisting of a next generation Adenovirus Vector Vaccine Platform and a manufacturing E.C7 human cell line, collectively the Etubics Platform. Clinical work to date shows that the Etubics Platform overcomes problems associated with existing adenovirus vectors. The Company’s Platform can be used to efficiently and rapidly develop immunotherapeutic drugs and preventive vaccines for a wide range of infectious diseases and cancers .
Statements herein relating to future financial, business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Etubics is a private company. Etubics cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward looking statements or historical experience include risks and uncertainties, including the failure by Etubics to secure and maintain relationships with collaborators; risks relating to the early state of Etubics’s product candidates under development; uncertainties relating to clinical trials and regulatory requirements and actions; risks relating to the commercialization, if any, of Etubics proposed product candidates; competitive risks to marketed products; dependence on the efforts of third parties; dependence on intellectual property; and risks that it may lack the financial resources and access to capital to fund its operations. Further information on the factors and risks that could affect Etubics’s offices, business, financial conditions and results of operations, are contained in Etubics’s documents on file at the Company. These forward-looking statements speak only as of the date of this press release and Etubics assumes no duty to update forward-looking statements.
Investor/Media contact: Ms. Ines Tucakovic Clark Phone: (206) 838-5110 Ext. 110 firstname.lastname@example.org